ITHACA, N.Y., Jan. 27, 2016 /PRNewswire/ -- Vybion (NY) conducted a webinar, sponsored by the Huntington's Disease Society of America (HSDA), for patients and caregivers on a new Gene Therapy drug called INT41. The company CEO described this new drug class called Intrabodies and how INT41 works in Huntington's Disease along with clinical development plans. The company believes that Intrabodies can achieve both the specificity and safety of monoclonal antibodies from which Intrabodies are developed and have numerous applications in disease that have "hard" targets. The Webinar is available for viewing at (https://www.youtube.com/watch?v=-_AJlAMdGbM&index=1&list=PLLQmMRDsNEY3oBm9cZ8sfb5Blh1Y3weG_).
INT41 is a preclinical first-in-class Intrabody Gene Therapy that has been shown to alleviate cognitive and motor function loss in an animal model and appears to function by inhibiting gene dysregulation, also observable in human patients prior to symptom onset, caused by a mechanism described in the Webinar. "It is important to engage early with the Huntington's Disease community to pave the way for clinical trials" Said Lee Henderson, Vybion CEO.
Lee Henderson, PhD
PO Box 4030
Ithaca, NY 14852
SOURCE Vybion, Inc.